Breakwater Biopharma Partners

Built for the trial after the one you're running now.

Fractional clinical operations leadership for Series A and B sponsors moving toward a registrational program — CRO oversight, site activation, TMF integrity, inspection readiness — without adding headcount you'll have to defend at the next raise.

Left of the line: vendor drift, enrollment variance, TMF debt.

Right of it: a study your board and an inspector can both follow.

Start a conversation

Why sponsors call

Three things we hear in the first fifteen minutes.

Rarely framed as an operations problem at first. Usually framed as a timeline problem, a CRO problem, or a board problem.

The CRO is running the study, and no one on our side can tell us whether it's running well.

Oversight exists on paper. What's missing is the small set of metrics, meeting structures, and escalation paths that turn a monthly status deck into an early warning.

Sites are activated, but enrollment keeps sliding a month at a time.

Activation and enrollment are different problems with different fixes. Treating them as one is why the forecast keeps moving without anyone being able to say why.

The next study is registrational, and the way we work today won't hold.

What carries a Phase 1 through — good people improvising fast — becomes the finding in a Phase 3 inspection. The gap is usually documentation and decision traceability, not effort.

Where we work

Senior operations capability, engaged for the part you actually need.

Breakwater works inside your team — in your systems, in your meetings, accountable for outcomes rather than deliverables alone.

Leadership

Fractional clinical operations lead

Acting head of clinical operations for sponsors who need the judgment of a VP before they can justify the salary of one.

Oversight

CRO selection and governance

RFP and bid defense support, contract and change-order review, governance cadence, performance metrics, and recovery when a partnership has gone sideways.

Execution

Site activation and enrollment risk

Country and site strategy, startup critical path, feasibility that survives contact with reality, and enrollment forecasting you can defend to a board.

Cost

Vendor and budget control

Study budget build, site payment structures, vendor scope comparison, invoice reconciliation, and monthly cost rollups that reconcile to accrual.

Quality

TMF integrity and inspection readiness

TMF health assessment and remediation, quality event handling, and readiness preparation well before an inspection is scheduled.

Scale

Infrastructure for the next phase

The SOPs, systems, roles, and vendor architecture a lean sponsor needs in place before a registrational program starts, not during it.

Fixed-scope engagement

The Scale Readiness Assessment

A structured diagnostic of your clinical operations function against six domains, ending in a rated picture of where you stand and a sequenced plan for closing the gaps that matter before your next study starts.

Six domains assessed

  • Study startup and site activation
  • CRO and vendor oversight
  • Data, biometrics, and reporting
  • Quality, TMF, and inspection readiness
  • Resourcing, roles, and governance
  • Program planning and forecasting
Typical duration
Four to six weeks, run alongside your active studies
Inputs
Document review, systems walkthrough, and structured interviews across your team and key vendors
Output
Maturity rating by domain, prioritized findings, and a remediation roadmap sequenced to your next milestone
If you continue
The assessment fee is credited against the first months of a fractional retainer
Ask about the assessment

Background

Twenty years on both sides of the sponsor–CRO relationship.

Breakwater is led by Deborah Goodman, who has spent roughly two decades in clinical operations across oncology and rare disease — inside sponsors and inside CROs, which is a useful thing to have been when a partnership needs repairing.

That work has spanned early-phase studies through registrational programs, and sites across North America, Europe, the United Kingdom, the Middle East, South Asia, and Africa. Small sponsors get the benefit of that range without carrying it as fixed cost.

Engagements are led personally. There is no bench of junior consultants behind this practice, which is deliberate — it caps how many clients Breakwater takes at once, and it means the person in your governance meeting is the person you hired.

Therapeutic focus
Oncology and rare disease
Phases
Phase 1 through registrational
Perspective
Sponsor-side and CRO-side
Geography
US, EU, UK, Israel, India, UAE, Australia, and parts of Africa
Client profile
Series A and B biopharma, typically pre-commercial

How engagements work

Three ways in, depending on how defined the problem already is.

Ongoing

Fractional retainer

A set number of days per month as your acting clinical operations lead. Best when you need continuity through a study rather than an answer to one question.

Diagnostic

Scale Readiness Assessment

Fixed scope, fixed fee, fixed timeline. Best when you know something needs to change before the next program and want it named precisely.

Defined

Project engagement

A specific piece of work with a clear end: a CRO selection, a TMF remediation, a budget rebuild, an inspection readiness push.

Get in touch

If any of this sounds like your current quarter, let's talk.

A first conversation is thirty minutes and costs nothing. If Breakwater isn't the right fit, you'll get a straight answer and, where possible, a better direction.

deborah@breakwaterbiopharma.com LinkedIn — Deborah Goodman Orlando, Florida · Working with sponsors across US, EU, and APAC time zones